Medtronic, Smiths Medical settle
This article was originally published in The Gray Sheet
Executive Summary
Insulin pump cross-licensing agreement closes all pending litigation between the firms and allows retention of existing device designs, Smiths Medical announces July 1. "This agreement allows both companies to continue business as usual without having to change any of the features or functionality" of the pumps, a release states. In August 2004, Medtronic filed against Smiths alleging that the Deltec Cozmo insulin pump infringed certain MiniMed patents (1"The Gray Sheet" Jan. 19, 2004, p. 3)...
You may also be interested in...
Abbott Acquires A Future For Its Diabetes Care Business; Where’s Bayer?
Access to a development partnership with insulin infusion pump manufacturer Smiths Medical could prove a critical component of Abbott Labs' $1.2 bil. purchase of diabetes management firm TheraSense
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.